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Development of Suspension Adapted 
Vero Cell Culture Process for 
Production of Viruses
Chun Fang Shen, PhD
Cell Culture Scale-Up
Human Health Therapeutics Research Center
chunfang.shen@nrc-cnrc.gc.ca
Background
 Vero cells are considered as the most widely accepted continuous cell 
line by the regulatory authorities (such as WHO) for the manufacture 
of viral vaccines for human use.
 The continuous Vero cell line has been used, after propagation on 
microcarriers, for the production of rabies, polio, enterovirus 71 and 
hantaan virus vaccines.
 The Vero cell line has gained worldwide acceptance as cell culture 
production platform in the vaccine field.
 The Vero cell culture technologies were explored for productions of 
many more anti-viral vaccines in the last two decades. 
Current Vero Cell Culture Technologies
 The growth of Vero cell is anchorage-dependent. They are labor 
intensive and limited in scale-up production when the Vero cell is grown 
in traditional two-dimensional culture methods and in microcarriers.
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Limitations of Anchorage-dependent Cell Culture 
Technologies in process scale-up
 Cells are dissociated enzymatically or 
mechanically, labor intensive.
 Growth is limited by surface area, 
which may limit product yields.
Vaccine manufacturing process using adherent cells in single-use bioreactors 
(Vero, 200-L scale) Calvosa & Seve. US 20110151506 A1
SEM of Vero cells cultured on 
microcarrier beads 
Suspension Cell Culture
High-scale virus production process overview with single-use bioreactor 
systems using suspension EB66 cells at 200-L scale (Madeline et al. 2015)
 Subculturing is a simple matter of dilution.
 There is little or no growth lag after splitting a suspension culture.
 Scale-up is straightforward.
Vero Cell Culture Media
 Media for anchorage Vero cell culture: 
 Serum-containing media: costly, lot-to-lot inconsistence, threat 
of contamination.
 Serum-free media:
• VP-SFM (Life technologies)
• OptiPro SFM (Life technologies)
• EX-CELL Vero SFM (SAFC Biosciences)
• ProVero (Lonza)
• HyQ SFM4MegaVir (Hyclone)
Benchmark of Commercial Serum-free Media for 
Vero Cell Cultures
Performance Indicators of culture medium 
• Maximum cell density in batch culture
• Cell doubling time
• Virus productivity
Comparison of Vero cell growth on Cytodex 1 microcarriers 
in five different serum-free media (Chen et al. 2011)
Current status of commercial serum-free media 
for Vero cell
• No commercial serum-containing or serum-free media is 
available for suspension Vero cell. 
• Maximum cell density of adherent Vero cell achieved in 
microcarriers batch culture is general lower than 2.5 x 106
cells/mL. 
• Doubling time of adherent Vero cell in microcarrier culture 
is 45 hours or longer. 
Sum up:
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Overview of Suspension Adapted Vero Cell 
• Advantage and benefit of suspension 
Vero cell culture process over adherent 
culture in large-scale manufacturing. 
 A Vero cell line (ATCC CCL-81 origin) 
has been adapted to grow in 
suspension in an in-house developed 
serum-free medium.
 The adapted cell was found genetically 
stable by short tandem repeat analysis.
 Tumorigenicity test of suspension 
adapted cell is in progress. 
Shake flask batch culture of suspension 
adapted Vero cell in serum-free and animal 
component free medium
Adaptation of Vero cell to grow in suspension and 
serum-free media at NRC Montreal
Suspension adapted Vero cell cultured in 125 mL shake flask and observation of culture under a 
microscope
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Comparison on virus productivity between adherent 
and suspension adapted Vero cells
• Production of vesicular stomatitis virus (VSV) 
in adherent (T175) and suspension adapted 
(SF, 125 mL shake flask) Vero cell cultures 
with medium replacement before the viral 
infection. 
• The suspension adapted cell showed better 
productivity than the adherent one
• Influenza virus was used as another model to 
investigate the virus productivity of suspension 
adapted Vero cell.
• The suspension adapted cell seems to have 
lost some productivity of hemagglutinin (HA).
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Production of VSV in a 3L bioreactor perfusion 
culture
 The cell density in the bioreactor reached 
6.8x106 cells/mL after 2 days of perfusion 
at 0.5 vvd and another day at 1 vvd before 
the virus infection (A).
 The VSV titer in the bioreactor culture was 
similar to that achieved in the shake flask 
control cultures infected at 6x106 cells/mL 
and was nearly one log higher than that in 
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